Sanofi (SNY) Tops Q4 EPS by 74c; offers FY24 guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Sanofi (SNY) shares slide following Q4 revenue miss
February 1, 2024 8:42 AM ESTSanofi (NASDAQ: SNY) shares are down premarket following its fourth-quarter earnings release, which saw revenue come in below consensus expectations.
The pharmaceutical and healthcare company reported Q4 EPS of EUR1.66, EUR0.74 better than the analyst estimate of EUR0.92. Revenue for the quarter was EUR10.92 billion versus the consensus estimate of EUR12.65 billion.
Q4 sales rose 9.3% year-on-year, with vaccine sales up... More
